Batu Biologics, an immunotherapy company working to develop ValloVax™, the first cellular anti-angiogenic cancer vaccine, has announced today the appointment of Dr. Hong Ma as Chief Scientific Officer. Ma – who has extensive business development and scientific consulting experience in domestic and international markets in the biotech and pharmaceutical industries – will provide oversight for R&D and business strategy for Batu Biologics.
Help employers find you! Check out all the jobs and post your resume.
